Marshall Wace LLP Sells 950,554 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS)

Marshall Wace LLP lessened its stake in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 27.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,534,378 shares of the company's stock after selling 950,554 shares during the period. Marshall Wace LLP owned about 1.12% of Gossamer Bio worth $2,281,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Monaco Asset Management SAM boosted its position in shares of Gossamer Bio by 39.5% during the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company's stock valued at $4,859,000 after purchasing an additional 1,520,721 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Gossamer Bio by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company's stock worth $2,037,000 after acquiring an additional 38,084 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Gossamer Bio by 1.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company's stock worth $1,123,000 after acquiring an additional 13,902 shares in the last quarter. Finally, Smith Moore & CO. boosted its holdings in Gossamer Bio by 32.7% in the fourth quarter. Smith Moore & CO. now owns 300,000 shares of the company's stock worth $271,000 after acquiring an additional 74,000 shares in the last quarter. Institutional investors own 81.23% of the company's stock.

Gossamer Bio Trading Down 2.1 %

NASDAQ GOSS opened at $0.96 on Monday. The business's fifty day moving average is $1.10 and its 200-day moving average is $0.98. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. The stock has a market capitalization of $217.75 million, a price-to-earnings ratio of -2.99 and a beta of 1.88. Gossamer Bio, Inc. has a one year low of $0.50 and a one year high of $1.55.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.15) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.15). The company had revenue of $9.38 million during the quarter, compared to analysts' expectations of $7.02 million. Equities research analysts predict that Gossamer Bio, Inc. will post -0.28 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on GOSS shares. The Goldman Sachs Group cut their price target on Gossamer Bio from $8.00 to $7.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. Wedbush reiterated an "outperform" rating and issued a $4.00 price target on shares of Gossamer Bio in a report on Friday, March 14th. Finally, HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Gossamer Bio in a research note on Tuesday, March 18th.

Gossamer Bio Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.